HeyJaredHormone Insight
Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.
- Indexed episodes, last 90 days
- 2
- Latest publication
- Sep 11, 2026
- Audience
- Checking…
- Earliest in this view
- Aug 22, 2026
Latest episodes
CATALYST: Mifepristone, HbA1c and Treatment Burden -- Clinical Evidence for Doctors (opens the original)
Read excerpt
An HbA1c benefit is only one part of a clinical decision. This Hormone Insight evidence review examines the randomized treatment phase of CATALYST: mifepristone in selected adults with difficult-to-control type 2 diabetes and biochemical hypercortisolism. We review the population and trial design, the 24-week HbA1c and weight results, and findings on blood pressure, hypokalaemia, treatment discontinuation and serious adverse events. We also discuss missing data, secondary-endpoint multiplicity a
SOUL: Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (opens the original)
Read excerpt
SOUL is a large randomized trial of oral semaglutide in adults with type 2 diabetes and established cardiovascular or kidney disease. In this Hormone Insight clinical evidence discussion, we cover the five-part PICO, the primary MACE result, absolute event rates, the non-significant kidney secondary outcome, patient selection, and limits of generalization. Fahad narration, clean voice-only production, no music. Primary source: PMID 40162642. DOI 10.1056/NEJMoa2501006. For healthcare professional
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.